Table 2.

Hazard ratios (95% CI) of cancers by quintile of PRS, UK Biobank^*

Cancer site	Q1 (low)	Q2	Q3	Q4	Q5	P trend †
Prostate
No. of cases	316	566	795	1037	1716
HR (95% CI)	1.00 (Referent)	1.78 (1.55 to 2.05)	2.54 (2.23 to 2.89)	3.34 (2.94 to 3.79)	5.63 (5.00 to 6.35)	<.001
Breast
No. of cases	413	639	774	996	1518
HR (95% CI)	1.00 (Referent)	1.56 (1.38 to 1.76)	1.89 (1.68 to 2.13)	2.45 (2.18 to 2.74)	3.77 (3.39 to 4.21)	<.001
Colorectum
No. of cases	257	399	460	554	788
HR (95% CI)	1.00 (Referent)	1.56 (1.33 to 1.82)	1.80 (1.54 to 2.10)	2.16 (1.87 to 2.51)	3.08 (2.68 to 3.55)	<.001
Lung
No. of cases	221	266	300	342	379
HR (95% CI)	1.00 (Referent)	1.20 (1.01 to 1.44)	1.36 (1.15 to 1.62)	1.54 (1.30 to 1.82)	1.71 (1.45 to 2.02)	<.001
Kidney
No. of cases	76	100	99	122	148
HR (95% CI)	1.00 (Referent)	1.32 (0.98 to 1.77)	1.30 (0.97 to 1.76)	1.61 (1.21 to 2.14)	1.96 (1.48 to 2.58)	<.001
Bladder
No. of cases	62	89	99	126	137
HR (95% CI)	1.00 (Referent)	1.43 (1.03 to 1.97)	1.6 (1.16 to 2.19)	2.04 (1.5 to 2.76)	2.21 (1.64 to 2.99)	<.001
Ovary
No. of cases	60	55	62	73	108
HR (95% CI)	1.00 (Referent)	0.92 (0.64 to 1.32)	1.03 (0.72 to 1.47)	1.22 (0.86 to 1.71)	1.81 (1.32 to 2.48)	<.001
Pancreas
No. of cases	42	60	71	119	140
HR (95% CI)	1.00 (Referent)	1.43 (0.96 to 2.12)	1.70 (1.16 to 2.48)	2.84 (2.00 to 4.03)	3.37 (2.39 to 4.76)	<.001

^*Cutoff points for quintiles were based on the distribution of all study participants. Hazard ratios (HRs) were estimated using Cox regression and adjusted for age, birth cohort, genotyping array, top 10 principal components for ancestry, and sex (for nonsex-specific cancer only). CI = confidence interval; PRS = polygenic risk score.

^†Two-sided Wald tests were performed with a type I error of 0.05.